HOME >> MEDICINE >> NEWS
GroPep completes final milestone of the path malaria vaccine initiative

Adelaide biotechnology company GroPep has completed the manufacture of two vaccine antigens as part of the project funded by the international PATH Malaria Vaccine Initiative (MVI).

GroPep will supply these vaccine antigens to the MVI for formulation and subsequent use in human clinical trials - expected to start in 2007.

Listed biopharmaceutical company GroPep Limited (ASX :GRO) announced today that it had successfully completed the second and final milestone of its agreement with the PATH Malaria Vaccine Initiative to manufacture malaria vaccine candidates for testing in human clinical trials.

GroPep reported the successful completion to Milestone 1 of the vaccine project in September 2003, developing scalable manufacturing processes for two malaria vaccine candidates.

Milestone 2 required scale-up of production and manufacturing to appropriate quality standards to enable the potential malaria vaccines to be tested in human safety trials. A sufficient quantity of each vaccine antigen has been manufactured.

PATH is an international, non-profit organisation that creates sustainable, culturally relevant solutions allowing global communities to break long-standing cycles of poor health. The Malaria Vaccine Initiative's (MVI) mission is to accelerate the development of malarial vaccines for the developing world. Malaria kills 7000 people each week and there is no vaccine.

MVI Director, Dr Melinda Moree congratulated GroPep on completing this important project milestone. "GroPep has made an important contribution to the quest to develop a vaccine against malaria."

GroPep's CEO, Bob Finder said that the manufacturing project had provided GroPep with a number of technical challenges that had been successfully met.

"As a Company, we are pleased to have successfully completed our part of the project, which may ultimately reduce the impact of this disease on millions of people worldwide," he said.
'"/>

Contact: Tony Mitchell
investorrelations@gropep.com.au
61-883-547-700
Research Australia
19-Dec-2005


Page: 1 2

Related medicine news :

1. GroPep awarded key patent for infertility treatment in Europe
2. GroPep starts Phase 1 infertility trial
3. GroPep to pursue promising asthma drug following preclinical study results
4. GroPep licenses technology to TGR BioSciences
5. GroPep news: Key psoriasis patent granted in Japan and new asthma patent filed for GroPep drug
6. Asthmatx completes enrollment in pivotal study of bronchial thermoplasty
7. Acrux completes enrollment in key phase 2 trial
8. MacroChem completes patient enrollment for Phase II trial of EcoNail for treatment of onychomycosis
9. Im a Kid Too project completes first phase
10. 6 finalists compete for achievement in operations research
11. Heart Rhythm Society publishes final recommendations for heart patients

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... ... Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, ... guideline updates for the primary prevention of cardiovascular diseases during the 15th ...
(Date:10/13/2017)... York, NY (PRWEB) , ... October 13, 2017 , ... ... influential people in business to advocate for action towards gender equality at their inaugural ... views from around the globe, and reached a social audience of over 3 million. ...
(Date:10/13/2017)... ... 2017 , ... “The Journey: From the Mountains to the Mission Field”: the ... in the Philippines. “The Journey: From the Mountains to the Mission Field” is the ... She has taught all ages and currently teaches a class of ladies at her ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... ANGELES (PRWEB) , ... October 12, 2017 , ... ... Parsa Mohebi Hair Restoration, has recently contributed a medical article to the newly ... on cosmetictown.com. Dr. Mohebi’s article spotlights the hair transplant procedure known as ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... , Sept. 18, 2017 ... fields of bioinformatics and immune engineering, today ... protective avian influenza A (H7N9) vaccine. ... related to seasonal influenza and presents a ... on prior exposure to be effective. Using ...
(Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform for ... the first annual edition of its Global CSR Risk and Performance Index. ... by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data points ... ... ...
(Date:9/12/2017)... 12, 2017  ValGenesis Inc., the global leader ... pleased to announce the appointment of Dr. ... Board of Directors and Chairman of Advisory Board ... science companies to manage their entire validation lifecycle ... in this process. Furthermore, ValGenesis VLMS enables rigorous ...
Breaking Medicine Technology:
Cached News: